Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
TransAct Technologies Incorporated is a computer hardware business based in the US. TransAct Technologies Incorporated shares (TACT) are listed on the NASDAQ and all prices are listed in US Dollars. TransAct Technologies Incorporated employs 112 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$13.99|
|52-week range||$6.85 - $17.18|
|50-day moving average||$13.83|
|200-day moving average||$13.49|
|Wall St. target price||$20.33|
|Dividend yield||$0.09 (0.63%)|
|Earnings per share (TTM)||$-0.83|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-0.76%|
|1 month (2021-09-20)||-0.05%|
|3 months (2021-07-20)||6.57%|
|6 months (2021-04-20)||16.31%|
|1 year (2020-10-20)||88.07%|
|2 years (2019-10-18)||15.26%|
|3 years (2018-10-19)||15.22|
|5 years (2016-10-20)||97.32%|
Valuing TransAct Technologies Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TransAct Technologies Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
TransAct Technologies Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.91. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into TransAct Technologies Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
TransAct Technologies Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.4 million.
The EBITDA is a measure of a TransAct Technologies Incorporated's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$32.7 million|
|Gross profit TTM||$12.9 million|
|Return on assets TTM||-16.28%|
|Return on equity TTM||-27.99%|
|Market capitalisation||$138.7 million|
TTM: trailing 12 months
There are currently 30,756 TransAct Technologies Incorporated shares held short by investors – that's known as TransAct Technologies Incorporated's "short interest". This figure is 8.9% up from 28,231 last month.
There are a few different ways that this level of interest in shorting TransAct Technologies Incorporated shares can be evaluated.
TransAct Technologies Incorporated's "short interest ratio" (SIR) is the quantity of TransAct Technologies Incorporated shares currently shorted divided by the average quantity of TransAct Technologies Incorporated shares traded daily (recently around 31707.216494845). TransAct Technologies Incorporated's SIR currently stands at 0.97. In other words for every 100,000 TransAct Technologies Incorporated shares traded daily on the market, roughly 970 shares are currently held short.
However TransAct Technologies Incorporated's short interest can also be evaluated against the total number of TransAct Technologies Incorporated shares, or, against the total number of tradable TransAct Technologies Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TransAct Technologies Incorporated's short interest could be expressed as 0% of the outstanding shares (for every 100,000 TransAct Technologies Incorporated shares in existence, roughly 0 shares are currently held short) or 0.004% of the tradable shares (for every 100,000 tradable TransAct Technologies Incorporated shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TransAct Technologies Incorporated.
Find out more about how you can short TransAct Technologies Incorporated stock.
We're not expecting TransAct Technologies Incorporated to pay a dividend over the next 12 months.
TransAct Technologies Incorporated's shares were split on a 3:2 basis on 4 April 2004. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your TransAct Technologies Incorporated shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for TransAct Technologies Incorporated shares which in turn could have impacted TransAct Technologies Incorporated's share price.
Over the last 12 months, TransAct Technologies Incorporated's shares have ranged in value from as little as $6.85 up to $17.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TransAct Technologies Incorporated's is 1.9852. This would suggest that TransAct Technologies Incorporated's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
TransAct Technologies Incorporated designs, develops, and markets transaction-based and specialty printers and terminals in the United States and internationally. Its thermal and inkjet printers and terminals to generates labels, coupons, and transaction records, such as receipts, tickets, and other documents, as well as printed logging and plotting of data. The company also provides consumable products, including POS receipt paper, inkjet cartridges, ribbons, and other printing supplies, as well as replacement parts; maintenance, repair, and testing services; and refurbished printers. In addition, it offers EPICENTRAL print system, a software solution that enables casino operators to create promotional coupons and marketing messages, and print them at the slot machine; and technical support services, as well as spare parts and accessories. Further, the company provides BOHA! terminal for the food service technology solution market that combines hardware and software components in a device that includes an operating system, touchscreen, and one or two thermal print mechanisms. It markets its products under the BOHA!, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brands for restaurant, point of sale automation and banking, casino and gaming, lottery, oil and gas, and hospitality markets, as well as government. The company sells its products to original equipment manufacturers, resellers, and distributors, as well as directly to end-users through online Webstore transactsupplies.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.